Center for Biological Diversity filed 2 comments on this docket between Aug 4, 2021 and May 19, 2023. 1 other organizations filed here. The comment window closed 988d ago.
Please find the attached comment letter from the Center for Biological Diversity regarding the effects determination for fluazaindolizine. Docket EPA-HQ-OPP-2020-0065.
Filed on regulations.gov — full text not in the inline record.
An application for the registration of the new active ingredient, fluazaindolizine, has been submitted to the Agency. The application includes one end-use-product and a tolerance petition
View on regulations.gov →